Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Bhavana Konda
- Target Recruit Count
- 53
- Registration Number
- NCT01723202
- Locations
- 🇺🇸
The University of Texas-MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 2
- Registration Number
- NCT01721603
- Locations
- 🇺🇸
University of San Francisco, California, San Francisco, California, United States
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01701037
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 870
- Registration Number
- NCT01682083
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 704
- Registration Number
- NCT01597908
- Locations
- 🇬🇧
Novartis Investigative Site, Swansea, United Kingdom
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 423
- Registration Number
- NCT01584648
- Locations
- 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT01336634
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.